News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA Mulls Killing GlaxoSmithKline’s Avandia Safety Study
April 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. regulators are considering ending a safety study on GlaxoSmithKline's (GSK.L) diabetes drug Avandia, the Wall Street Journal reported on Sunday, saying the move could also jeopardize the drug's presence in the U.S market.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
FDA
Approvals
Food and Drug Administration (FDA)
GSK
MORE ON THIS TOPIC
Breast cancer
AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote
May 27, 2026
·
4 min read
·
Tristan Manalac
Cancer
Kura’s encouraging cancer drug data could unlock $2B market opportunity
May 27, 2026
·
2 min read
·
Tristan Manalac
Insights
Germany can produce biotech winners. Europe must back them better.
May 27, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Manufacturing
Niowave, fresh from Novartis deal, starts building $75M radioisotope plant
May 26, 2026
·
2 min read
·
Nick Paul Taylor
